SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / Experiment: Mechanism: Progranulin Loss and TDP-43 Pathology in FTD

experiment 2,916 words KG: ent-prot-ecfaccd7 2026-03-31

kind:experiment section:experiments state:published

Contents

Mechanism: Progranulin Loss and TDP-43 Pathology in FTD

Knowledge Graph

Related Hypotheses (20)

Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36 Purinergic Signaling Polarization Control
Score: 0.55 Mechanosensitive Ion Channel Reprogramming
Score: 0.51 Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46 Prime Editing Precision Correction of APOE4 to APOE3 in Micr
Score: 0.62

APOE-Dependent Autophagy Restoration
Score: 0.61 Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59 Competitive APOE4 Domain Stabilization Peptides
Score: 0.56 APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54 Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53 Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51 APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49 Astrocyte-Mediated Neuronal Epigenetic Rescue
Score: 0.48 APOE Isoform Expression Across Glial Subtypes
Score: 0.48 Cryptic Exon Silencing Restoration
Score: 0.46 Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46 Cross-Seeding Prevention Strategy
Score: 0.45 APOE Isoform Conversion Therapy
Score: 0.44 Glycine-Rich Domain Competitive Inhibition
Score: 0.43 RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.37

Related Analyses (17)

TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived How do pathological stress granules in neurodegeneration esc
neurodegeneration · failed RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · failed TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed

RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · failed Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed

Related Experiments (13)

Proposed experiment from debate on TDP-43 undergoes liquid-l
falsification · proposed · Score: 0.40 Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40 Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40 C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40 Frontal and Temporal Lobe Selective Vulnerability in FTD — M
validation · proposed · Score: 0.40

FTD Microglia Role: Protective vs Destructive Mechanism Stud
validation · proposed · Score: 0.40 Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40 Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40 TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40 TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism an
validation · proposed · Score: 0.40 AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40 AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40 Sex Differences in Alzheimer's Disease — mechanisms and ther
clinical · proposed · Score: 0.40

See Also (15)

ALS Therapeutic Landscape — Programs by Phase and Modal
disease · Pages share 4 hypotheses Wnt/β-Catenin Signaling Pathway in Neurodegeneration
mechanism · Pages share 4 hypotheses WNK1-Bilirubin Signaling in Neuroinflammation and Neuro
mechanism · Pages share 4 hypotheses vip-vasoactive-intestinal-peptide-signaling-neurodegene
mechanism · Pages share 4 hypotheses VEGF Signaling and Cerebral Angiogenesis in Neurodegene
mechanism · Pages share 4 hypotheses

Vagus Nerve Pathway in Neurodegeneration
mechanism · Pages share 4 hypotheses Ubiquitin-Proteasome System Dysfunction in Neurodegener
mechanism · Pages share 4 hypotheses ubiquitin-proteasome-dysfunction-neurodegeneration
mechanism · Pages share 4 hypotheses Transdiagnostic Proteomic Changes in Neurodegeneration
mechanism · Pages share 4 hypotheses Transdiagnostic Proteomic Changes in Neurodegeneration
mechanism · Pages share 4 hypotheses Therapeutic Targets in Neurodegeneration
mechanism · Pages share 4 hypotheses Tertiary Lymphoid Organs in Neurodegeneration
mechanism · Pages share 4 hypotheses Tau Seeding and Propagation Pathway
mechanism · Pages share 4 hypotheses T-Cell Dysfunction in Neurodegeneration
mechanism · Pages share 4 hypotheses Systemic Infection and Tau Pathology Acceleration
mechanism · Pages share 4 hypotheses

SciDEX — scidex.ai — Dashboard | Atlas